Biogen Inc. (BIIB)
| Previous Close | 231.58 |
| Open | 229.29 |
| Bid | 226.15 x 100 |
| Ask | 226.61 x 100 |
| Day's Range | 224.82 - 231.95 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,228,777 |
| Market Cap | 32.938B |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | 28.31 |
| EPS (TTM) | 7.99 |
| Earnings Date | Jul 23, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 283.79 |
ZacksWhy Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ZacksIonis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
- Reuters
REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study. Shares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback in the search for new treatments for ALS, a rare neurodegenerative disease that affects the voluntary control of limbs and leads to breathing trouble.
